Replies to post #166063 on NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Neuro-Oncology, Volume 18, Issue suppl_6, 1 November 2016, Pages vi19

ATIM-09. SUCCESSFUL EXPERIENCE WITH CLINICAL TRIALS FOR HIGH GRADE GLIOMA IN A COMMUNITY SETTING.
Lars Anker Lavinia Dobrea Joy Nakhla Viorela Pop Lawrence Wagman

"Nationally, 20% of adults with cancer qualify for a clinical trial, yet only 3–5% consent. Over the last 4 years, we evaluated 58 patients for 8 different high grade glioma treatment trials, with 50% consenting (29/58). Of 19 patients who received at least one dose of study agent, 79% (15/19) completed treatment. Nationally, 30% of patients drop out of a clinical trial, whereas our voluntary withdrawal rate was only 3%. We had a 100% success rate in harvesting specimens for an autologous vaccine trial (DCVax®-L)."
https://academic.oup.com/neuro-oncology/article/18/suppl_6/vi19/2541936